Sulfasalazine
- Generic Name
- Sulfasalazine
- Brand Names
- Azulfidine, Salazopyrin, Salazopyrin En-tabs
- Drug Type
- Small Molecule
- Chemical Formula
- C18H14N4O5S
- CAS Number
- 599-79-1
- Unique Ingredient Identifier
- 3XC8GUZ6CB
- Background
Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA). Metabolized by intestinal bacteria, sulfasalazine is broken down into mesalazine and sulfapyridine, 2 compounds that carry ...
- Indication
In the US, sulfasalazine is indicated to treat mild to moderate ulcerative colitis and to prolong the remission period between acute attacks of ulcerative colitis. Sulfasalazine is also indicated as an adjunct therapy in severe ulcerative colitis.For the delayed-release tablet formulation, sulfasalazine is also indicated to treat rheumatoid arthritis in pedi...
- Associated Conditions
- Crohn's Disease (CD), Distal Ulcerative Colitis, Mild to Moderate Ulcerative Colitis, Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Proctitis, Rheumatoid Arthritis, Severe Ulcerative Colitis, Ulcerative Colitis in Remission
- Associated Therapies
- -
A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)
- Conditions
- Interventions
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 91
- Registration Number
- NCT02373202
- Locations
- 🇯🇵
Investigational Site Number 392039, Fukuoka-Shi, Japan
🇯🇵Investigational Site Number 392006, Sasebo-Shi, Japan
🇯🇵Investigational Site Number 392023, Takaoka-Shi, Japan
To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 217
- Registration Number
- NCT02057250
- Locations
- 🇨🇱
Investigational Site Number 152050, Santiago, Chile
🇨🇱Investigational Site Number 152007, Viña Del Mar, Chile
🇲🇽Investigational Site Number 484005, Monterrey, Mexico
A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2013-09-13
- Last Posted Date
- 2018-11-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 100
- Registration Number
- NCT01941095
- Locations
- 🇬🇷
Laiko General Hospital; Dept. of Pathophysiology-Uni of Athens, Athens, Greece
🇬🇷Uni Hospital of Ioannina; Rheumatology, Ioannina, Greece
🇬🇷General Hospital of Thessaloniki HIPPOKRATIO; Clinical Immunology Unit,2nd Dept of Internal Medicine, Thessaloniki, Greece
To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)
- First Posted Date
- 2013-01-15
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 202
- Registration Number
- NCT01768572
- Locations
- 🇺🇸
Investigational Site Number 840033, Fort Lauderdale, Florida, United States
🇺🇸Investigational Site Number 840150, Lansing, Michigan, United States
🇺🇸Investigational Site Number 840022, Dallas, Texas, United States
To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)
- Conditions
- Interventions
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 546
- Registration Number
- NCT01709578
- Locations
- 🇺🇸
Investigational Site Number 840018, Idaho Falls, Idaho, United States
🇺🇸Investigational Site Number 840058, Columbia, South Carolina, United States
🇺🇸Investigational Site Number 840124, Clarksburg, West Virginia, United States
Study of Sulfasalazine in Treating Painful Neuropathy
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2018-08-22
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 8
- Registration Number
- NCT01667029
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Effects of Methylnaltrexone in Comparison to Naloxone on Loperamide-induced Delay of the Oro-cecal, Whole-gut and Colon Transit Time.
- First Posted Date
- 2012-05-11
- Last Posted Date
- 2012-05-11
- Lead Sponsor
- University Medicine Greifswald
- Target Recruit Count
- 16
- Registration Number
- NCT01596764
- Locations
- 🇩🇪
Department of Clinical Pharmacology, Ernst-Moritz-Arndt-University Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany
Effects of 500 mg Immediate Release and Extended Release Methylnaltrexone on Loperamide-induced Delay of the Oro-cecal and Whole-gut Transit Time in Healthy Subjects
- First Posted Date
- 2012-05-11
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- University Medicine Greifswald
- Target Recruit Count
- 15
- Registration Number
- NCT01596777
- Locations
- 🇩🇪
Department of Clinical Pharmacology, Ernst-Moritz-Arndt-University Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany
Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma
- First Posted Date
- 2012-04-16
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 9
- Registration Number
- NCT01577966
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Effects of Sulfasalazine on BOLD Response to Alcohol Cues
- First Posted Date
- 2011-03-10
- Last Posted Date
- 2014-09-22
- Lead Sponsor
- The Mind Research Network
- Target Recruit Count
- 23
- Registration Number
- NCT01312129
- Locations
- 🇺🇸
The Mind Research Network, Albuquerque, New Mexico, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.